Meeting Coverage:

American Academy of Ophthalmology

AAO: 2024

Visual Field Progression in the LiGHT Trial

Show Description +

Gus Gazzard, FRCOphth, MA, MBBChir, MD, analyzes the 6-year rate of visual field progression in the laser in glaucoma and ocular hypertension (LiGHT) trial comparing selective laser trabeculoplasty (SLT) and medication as first-line glaucoma treatment. He reviews information presented during glaucoma subspecialty day at the American Academy of Ophthalmology annual meeting.

Posted: 10/25/2024

Up Next


Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, FRCOphth, MA, MBBChir, MD, analyzes the 6-year rate of visual field progression in the laser in glaucoma and ocular hypertension (LiGHT) trial comparing selective laser trabeculoplasty (SLT) and medication as first-line glaucoma treatment. He reviews information presented during glaucoma subspecialty day at the American Academy of Ophthalmology annual meeting.

Posted: 10/25/2024


Please log in to leave a comment.

More From AAO: 2024 Coverage